Virtual Network's Login.
Chairs: Michael Hallek, Louis Staudt, Stephan Stilgenbauer
Local Organizer: Kostas Stamatopoulos
SESSION I: MOLECULAR GENETICS AND PROFILING – WHAT HAVE WE LEARNED?
Pathogenic and therapeutic relevance of molecular signatures in aggressive lymphoma – G. Lenz
Genomic profiling and evolution of CLL – C. Wu
Molecular pathogenesis and treatment options in ALL – E. Campo
Genome, methylome and transcriptome sequencing in follicle center cell lymphoma (ICGC) – R. Siebert
Bcl-6 and related pathways in lymphoma genesis – R. Dalla-Favera
SESSION II: MOLECULAR PATHOGENESIS OF LYMPHOMA
Genomic profiling and the discovery of important pathways in lymphoma – R. Gascoyne
B cell receptor mediated signaling and targeted therapies – L. Staudt
B cell development and transformation: focus on the germinal center – R. Küppers
Mantle cell lymphoma – C. Mullighan
SESSION III: PROGNOSTIC MARKERS AND STAGING IN LYMPHOMA AND CLL – CONTROVERSIAL DEBATES
Diffuse large cell lymphoma:
Do we still need a clinical staging or can it be replaced by molecular signatures or profiling of the tumor?
Pro staging – M. Pfreundschuh
Pro molecular profiling – R. Gascoyne
Indolent lymphoma (follicular lymphoma)
The end of Ann Arbor staging and the beginning of molecular staging has come
Yes – G. Salles
No – F. Morschhauser
CLL:
The end of clinical staging alone has come – every treatment decision will be made after genetic profiling?
Yes – S. Stilgenbauer
No – E. Montserrat
SESSION IV: CONVENTIONAL CHEMO (IMMUNE) THERAPIES – STATE OF THE ART 2014
Diffuse large cell lymphoma – G. Salles
Indolent lymphoma – G. Salles
CLL – M. Hallek
Hodgkin – P. Borchmann
SESSION V: STEM CELL TRANSPLANTATION IN LYMPHOID MALIGNANCIES –
THE TIME IS OVER (OR NOT)? CONTROVERSIAL DEBATES
DLBCL
Pro transplant – U. Vitolo
Contra transplant – M. Pfreundschuh
Indolent Lymphomas
Pro transplant – S. Montoto
Contra transplant – M. Federico
CLL
Pro transplant – P. Dreger
Contra transplant – J. Gribben
SESSION VI: NOVEL THERAPEUTICS TARGETING DISTINCT KINASES OR PATHWAYS IN LYMPHOID MALIGNANCIES
BCL-2 inhibitors – J. Seymour
BTK inhibitors in CLL – P. Hillmen
BTK inhibitors in mantle cell lymphoma – S. Rule
BTK inhibitors in Waldenströms macroglobulinemia – S. Treon
Alternative BTK inhibitors (other than ibrutinib) – J. Brown
PI3K inhibitors – R. Furman
Novel type 2 antibodies – V. Goede
CART – D. Porter
Bispecific antibodies – R. Bargou
Antibody-drug conjugates – F. Morschhauser
SESSION VII: STRATEGIES FOR FUTURE CLINICAL TRIALS AND CONCEPTS FOR LYMPHOMA TREATMENT
Diffuse large cell lymphoma – K. Dunleavy
CLL – P. Hillmen
Mantle cell lymphoma – M. Dreyling
Follicular lymphoma. LYSA – G. Salles
